Use of a 2.5% Cross-Linked Polyacrylamide Hydrogel in the Management of Joint Lameness in a Population of Flat Racing Thoroughbreds: A Pilot Study.

Autor: de Clifford LT; Matamata Veterinary Services Limited, Matamata, New Zealand. Electronic address: leigh@matavet.co.nz., Lowe JN; Innovative Medical Solutions Limited, New Zealand., McKellar CD; AK & K Equine Services, Victoria, Australia., Bolwell C; Massey University, Massey Equine, Palmerston North, New Zealand., David F; Equine Veterinary Medical Center - Al Shaqab, A member of Qatar Foundation, Al Rayyan, Doha, Qatar.
Jazyk: angličtina
Zdroj: Journal of equine veterinary science [J Equine Vet Sci] 2019 Jun; Vol. 77, pp. 57-62. Date of Electronic Publication: 2019 Feb 27.
DOI: 10.1016/j.jevs.2019.02.012
Abstrakt: Osteoarthritis is one of the most common disease processes effecting equine athletes, causing up to 60% of all lameness. This prospective longitudinal study reports on the effect of treatment of carpal and metacarpophalangeal joint lameness with 2.5% cross-linked polyacrylamide hydrogel (PAAG). A total of 49 flat-racing Thoroughbreds at a single training facility were included in the study. The results show a significant improvement in lameness grades at weeks 1 (P < .01), 4 (P < .001), 12 (P < .001), and 24 (P < .001) when compared to baseline lameness at week 0. This pilot study suggests that 2.5% cross-linked PAAG is a safe and effective joint treatment for managing joint lameness in Thoroughbred racehorses and warrants further blinded and controlled studies to fully evaluate the efficacy of the 2.5% cross-linked PAAG and its mode of action.
(Copyright © 2019 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: